Search Results
11 protocol(s) meet the specified criteria
Randomized Phase III Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Compared with CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

Multicenter, Phase I, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies

Pilot Trial Evaluating the Combination of Reolysin and Carfilzomib in Multiple Myeloma

Expanded Access Program for Ivosidenib (AG-120) Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia with an IDH1 Mutation

Open-Label, Dose-Escalation and Multicenter Study to Evaluate the Safety and Pharmacokinetics of SAR650984 in Patients with Relapsed/Refractory Multiple Myeloma

Phase I Study of BLU-285 in Patients with Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies

Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid versus Zoledronic Acid after Definite Radiation Therapy

Phase IB Study of the Safety and Pharmacokinetics of Atezolizumab (Anti Pd L1 Antibody) Alone or in Combination with an Immumomodulatory Drug and/or Daratumumab in Patients with Multiple Myeloma (Relapsed/Refractory and Post Autologous Stem Cell Transplantation)

Phase II, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

Phase II, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement